Cargando…

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213878/ https://www.ncbi.nlm.nih.gov/pubmed/32345630 http://dx.doi.org/10.1136/jitc-2020-000878corr1

Ejemplares similares

Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
Publicado: (2020)

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
por: Tsimberidou, Apostolia M., et al.
Publicado: (2018)

Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
por: Remon, J., et al.
Publicado: (2020)

Correction: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Publicado: (2023)

Correction: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Publicado: (2020)

Author Correction: The immuno-oncological challenge of COVID-19
por: Derosa, Lisa, et al.
Publicado: (2022)

Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee
por: Gastman, Brian, et al.
Publicado: (2020)

Immunotherapies and Combination Strategies for Immuno-Oncology
por: Barbari, Cody, et al.
Publicado: (2020)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Correction: Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality
Publicado: (2014)

Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer
por: Romero, Pedro J, et al.
Publicado: (2013)

Immuno-Oncology: Emerging Targets and Combination Therapies
por: Marshall, Henry T., et al.
Publicado: (2018)

Correction: The american pediatric society and society for pediatric research joint statement against racism and social injustice
por: Abman, Steven H., et al.
Publicado: (2021)

Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Publicado: (2023)

Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
por: Vafaizadeh, Vida, et al.
Publicado: (2020)

Correction: Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
por: Shao, Fuqiang, et al.
Publicado: (2023)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Publicado: (2021)

Correction: Clinical indications and triaging for adult transthoracic echocardiography: a statement by the British Society of Echocardiography
por: Bennett, Sadie, et al.
Publicado: (2023)

Author Correction: A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology
por: Candini, Olivia, et al.
Publicado: (2020)

Greater patient access to immuno-oncology therapies—what can policymakers do?
por: de Lorenzo, Francesco, et al.
Publicado: (2015)

Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
por: Zhang, Jiajia, et al.
Publicado: (2018)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Publicado: (2023)

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
por: Vranic, Semir, et al.
Publicado: (2020)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy
por: Bonfá, Giuliano, et al.
Publicado: (2020)

Natural killer cell: An immuno-oncology novel target for cancer therapy?
por: Shwetha, H. R, et al.
Publicado: (2017)

Correction: IL-6 and Mouse Oocyte Spindle
por: Banerjee, Jashoman, et al.
Publicado: (2012)

Correction to: Position statement of the Spanish society of pediatric rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: part 1 (screening)
por: Núñez Cuadros, Esmeralda, et al.
Publicado: (2022)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
por: Tawbi, Hussein A, et al.
Publicado: (2023)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Correction to: Parma consensus statement on metabolic disruptors
por: Heindel, Jerrold J., et al.
Publicado: (2017)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_078bur1g9qgkhptd069567prss